CHESTERFIELD, Mo., Aug. 7, 2019 /PRNewswire/ -- Reliv
International, a 30-year-old wellness company located in
Chesterfield, MO, announced today
that Dr. Alfredo Galvez has been
appointed as the company's Chief Scientific Advisor. Galvez
has been associated with Reliv since 2013 and is best known for his
groundbreaking work with lunasin, a naturally occurring soy
peptide. Through scientific research and clinical
trials, Galvez has proven that lunasin affects gene expression
and is the first dietary ingredient shown to promote optimal health
at the epigenetic level.
"Having Dr. Galvez in this role is extremely exciting," Reliv
CEO, Ryan Montgomery said when he
made the announcement. "His revolutionary work in epigenetics
is going to be the biggest thing that we've seen in our 30-year
history, and promises to be a game changer for both the wellness
community and Reliv."
Galvez serendipitously discovered the soy peptide in 1996
as a postdoctoral researcher at UC Berkeley. He has a PhD in
Genetics from UC Davis, majoring in molecular biology and
cytogenetics. After completing his PhD, Galvez worked for the
USDA-ARS at Washington State University
and at the University of California
Berkeley as a Research Biochemist and Geneticist. He
currently holds 10 issued and two pending US patents on the lunasin
technology.
Through Galvez, Reliv has exclusive rights to proprietary
extraction processes and a novel epigenetic bioassay to
produce highly bioactive (effective) and concentrated forms of
lunasin. Reliv currently owns three patents relating to
lunasin, and Galvez firmly believes that the company is way
ahead of the curve in harnessing the power of this clinically
proven superfood.
"You can't change your DNA blueprint, but you can influence how
that DNA expresses itself," Galvez said. "And with LunaRich®,
the first epigenetic superfood, Reliv has become the world's
first nutritional epigenetics company."
Dr. Galvez is currently developing new product lines that
will combine the power of lunasin and hemp extract. He believes
that the synergistic effects of this formulation will provide
health benefits that include cholesterol management, inflammation
reduction, antioxidant benefits, improved immunity, cellular
health, and more. "Reliv has always endeavored to remain on the
cutting edge of nutritional science and there are no other
ingredients out there more innovative and exciting than lunasin and
hemp extract," he said.
Montgomery and Galvez believe that Reliv is leading the way in
the budding field of nutritional epigenetics. Montgomery
stated, "Reliv is committed to building on this emerging science
and developing nutritional solutions with lunasin and other
plant-based nutrients that help people take control of their
lives."
"We're at the beginning of a nutritional revolution, and Reliv
is leading the way," Galvez said.
About Reliv International, Inc.
Reliv International, based in Chesterfield, MO, produces nutritional
supplements that promote optimal nutrition. Reliv supplements
address core nutrition, targeted solutions and overall
wellness through its line of RLV hemp extracts. Reliv is the
exclusive provider of LunaRich® products, which optimize levels
of lunasin, a soy peptide that works at the epigenetic level
to promote optimal health. The company sells its products through
an international network marketing system of independent
distributors in 12 countries. Learn more about Reliv
at reliv.com, or
on Facebook, Twitter or Instagram.
Statements made in this news release that are not historical
facts are "forward-looking" statements (as defined in the Private
Securities Litigation Reform Act of 1995) that involve risks and
uncertainties and are subject to change at any time. These
forward-looking statements may include, but are not limited to,
statements containing words such as "may," "should," "could,"
"would," "expect," "plan," "anticipate," "believe," "estimate,"
"predict," "potential," "continue" or similar expressions. Factors
that could cause actual results to differ are identified in the
public filings made by Reliv with the Securities and Exchange
Commission. More information on factors that could affect Reliv's
business and financial results are included in its public filings
made with the Securities and Exchange Commission, including its
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q,
copies of which are available on the Company's web
site, reliv.com.
Contact: Kurt Wulff
636.733.1433
kwulff@relivinc.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dr-alfredo-galvez-appointed-as-reliv-internationals-chief-scientific-advisor-300898192.html
SOURCE Reliv International